26 related articles for article (PubMed ID: 20121334)
1. Correlates of the preoperative level of CA125 at presentation of ovarian cancer.
Cramer DW; Vitonis AF; Welch WR; Terry KL; Goodman A; Rueda BR; Berkowitz RS
Gynecol Oncol; 2010 Dec; 119(3):462-8. PubMed ID: 20850174
[TBL] [Abstract][Full Text] [Related]
2. Insight into the function of tetranectin in human diseases: A review and prospects for tetranectin-targeted disease treatment.
Iram S; Rahman S; Choi I; Kim J
Heliyon; 2024 Jan; 10(1):e23512. PubMed ID: 38187250
[TBL] [Abstract][Full Text] [Related]
3. The relationship between the expression of TN and the efficiency of posterior spinal V osteotomy in patients with traumatic kyphosis.
Jiang G; Zhang Y; Sun X
Medicine (Baltimore); 2018 Feb; 97(5):e9555. PubMed ID: 29384840
[TBL] [Abstract][Full Text] [Related]
4. High Intratumoral Expression of Tetranectin Associates with Poor Prognosis of Patients with Gastric Cancer after Gastrectomy.
Chen H; Li H; Zhao J; Peng P; Shao M; Wu H; Wang X; Chen L; Zhang Q; Ruan Y; Liu F; Sun Y
J Cancer; 2017; 8(17):3623-3630. PubMed ID: 29151948
[TBL] [Abstract][Full Text] [Related]
5. Tetranectin as a Potential Biomarker for Stable Coronary Artery Disease.
Chen Y; Han H; Yan X; Ding F; Su X; Wang H; Chen Q; Lu L; Zhang R; Jin W
Sci Rep; 2015 Dec; 5():17632. PubMed ID: 26621497
[TBL] [Abstract][Full Text] [Related]
6. Towards an animal model of ovarian cancer: cataloging chicken blood proteins using combinatorial peptide ligand libraries coupled with shotgun proteomic analysis for translational research.
Ma Y; Sun Z; de Matos R; Zhang J; Odunsi K; Lin B
OMICS; 2014 May; 18(5):280-97. PubMed ID: 24660652
[TBL] [Abstract][Full Text] [Related]
7. [Interest of CA 125 level in management of ovarian cancer].
Coussy F; Chéreau E; Daraï E; Dhombres F; Lotz JP; Rouzier R; Selle F
Gynecol Obstet Fertil; 2011 May; 39(5):296-301. PubMed ID: 21515085
[TBL] [Abstract][Full Text] [Related]
8. Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma.
Szajnik M; Czystowska-Kuźmicz M; Elishaev E; Whiteside TL
Expert Rev Mol Diagn; 2016 Aug; 16(8):811-26. PubMed ID: 27268121
[TBL] [Abstract][Full Text] [Related]
9. The prognostic value of pre-operative serum tetranectin, CA-125 and a combined index in women with primary ovarian cancer.
Høgdall CK; Nørgaard-Pedersen B; Mogensen O
Anticancer Res; 2002; 22(3):1765-8. PubMed ID: 12168866
[TBL] [Abstract][Full Text] [Related]
10. Serum tetranectin as a preoperative indicator for postoperative complications in Danish ovarian cancer patients.
Begum FD; Høgdall E; Christensen IJ; Christensen L; Kjaer SK; Blaakaer J; Petri AL; Høgdall C
Gynecol Oncol; 2010 Jun; 117(3):446-50. PubMed ID: 20304468
[TBL] [Abstract][Full Text] [Related]
11. The prognostic value of pretherapeutic tetranectin and CA-125 in patients with relapse of ovarian cancer.
Deng X; Høgdall EV; Høgdall CK; Nørgaard-Pedersen B; Jørgensen M; Nielsen H; Engelholm SA
Gynecol Oncol; 2000 Dec; 79(3):416-9. PubMed ID: 11104612
[TBL] [Abstract][Full Text] [Related]
12. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
Begum FD; Høgdall E; Kjaer SK; Blaakaer J; Christensen IJ; Christensen L; Høgdall C
Gynecol Oncol; 2009 May; 113(2):221-7. PubMed ID: 19261323
[TBL] [Abstract][Full Text] [Related]
13. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV
Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388
[TBL] [Abstract][Full Text] [Related]
14. Serum tetranectin is a significant prognostic marker in ovarian cancer patients.
Begum FD; Høgdall E; Christensen IJ; Kjaer SK; Blaakaer J; Christensen L; Høgdall C
Acta Obstet Gynecol Scand; 2010; 89(2):190-8. PubMed ID: 20121334
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
